Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02093429 · ClinicalTrials.gov registry record · Phase 1
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02093429 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 6 participants.
The verdict
NCT02093429, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The study design includes a 3-dose randomization phase to determine effective doses of INCB047986 in patients with myelodysplastic syndrome (MDS) who are refractory or unlikely to respond to erythropoiesis-stimulating agents (ESAs) followed by an extension phase.
Interventions
- DRUG INCB047986
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02093429
The ClinicalTrials.gov registry entry for NCT02093429 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INCB047986 is the first listed.
NCT02093429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02093429 about?
NCT02093429 is a clinical study titled "Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)". The study design includes a 3-dose randomization phase to determine effective doses of INCB047986 in patients with myelodysplastic syndrome (MDS) who are refractory or unlikely to respond to erythropoiesis-stimulating agents (ESAs) followed by an extension phase.
What is the current status of trial NCT02093429?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2014-01. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02093429?
The interventions under investigation include: INCB047986 (DRUG).
Who is sponsoring clinical trial NCT02093429?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.